Holen Sie sich die Stockscreener-App
1.39
2.80%
-0.04
Handel nachbörslich:
1.39
Schlusskurs vom Vortag:
$1.43
Offen:
$1.38
24-Stunden-Volumen:
198.42K
Relative Volume:
0.32
Marktkapitalisierung:
$70.74M
Einnahmen:
$96.63M
Nettoeinkommen (Verlust:
$-63.32M
KGV:
-0.9521
EPS:
-1.46
Netto-Cashflow:
$-54.55M
1W Leistung:
-16.77%
1M Leistung:
-14.72%
6M Leistung:
-48.90%
1J Leistung:
-70.36%
1-Tages-Spanne:
$1.32
$1.43
1-Wochen-Bereich:
$1.32
$1.67
52-Wochen-Spanne:
$1.32
$4.69
Akoya Biosciences Inc Stock (AKYA) Company Profile
Firmenname
Akoya Biosciences Inc
Sektor
Telefon
855.896.8401
Adresse
100 CAMPUS DRIVE, MARLBOROUGH
Vergleichen Sie AKYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.39 | 70.74M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
495.27 | 181.97B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
229.06 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
94.93 | 46.83B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
223.85 | 32.94B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.23 | 17.65B | 17.28B | 108.00M | 391.00M | 0.20 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Herabstufung | Craig Hallum | Buy → Hold |
| 2024-08-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Buy |
| 2022-11-03 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-06-22 | Eingeleitet | BTIG Research | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-05-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Akoya Biosciences Inc Aktie (AKYA) Neueste Nachrichten
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 30.8% in March - Defense World
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges - Investing.com
This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Akoya Biosciences’ (AKYA) Equal Weight Rating Reaffirmed at Stephens - Defense World
Akoya Biosciences Shares Fall After Downgrade From Stephens - MarketScreener
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Stephens Downgrades Akoya Biosciences to Equalweight From Overweight, Price Target is $1.80 - Marketscreener.com
Tikvah to oppose Quanterix-Akoya Biosciences merger By Investing.com - Investing.com Australia
Tikvah to oppose Quanterix-Akoya Biosciences merger - Investing.com India
Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences - Business Wire
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences - Marketscreener.com
Key Investor Fights Back: Quanterix Merger Under Fire Over Valuation Concerns - Stock Titan
Akoya Biosciences (AKYA) to Release Quarterly Earnings on Monday - Defense World
Akoya Biosciences Reports 2024 Financial Results - TipRanks
Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates - MSN
Akoya Biosciences (NASDAQ:AKYA) Receives Overweight Rating from Stephens - Defense World
Akoya Biosciences Shares Down 6.4% After Stock Offering… -June 08, 2023 at 10:10 am EDT - Marketscreener.com
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges - Investing.com Australia
Akoya: Q4 Earnings Snapshot - Milford Mirror
Akoya Biosciences earnings missed by $0.01, revenue topped estimates - Investing.com Australia
Akoya Biosciences, Inc. Q4 Loss Decreases, But Misses Estimates - Nasdaq
Akoya Biosciences, Inc. SEC 10-K Report - TradingView
Kent Lake urges Quanterix to address questions regarding Akoya deal -March 17, 2025 at 04:28 pm EDT - Marketscreener.com
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results Amid Pending Acquisition by Quanterix Corporation - Nasdaq
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results - GlobeNewswire
Quanterix Merger Under Fire: Top Investor Reveals Shocking 82% Value Disparity - Stock Titan
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today’s Earnings Call - Bluefield Daily Telegraph
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of “Hold” by Brokerages - Defense World
Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger -March 11, 2025 at 10:40 am EDT - Marketscreener.com
Quanterix Merger Under Fire: 7.25% Stakeholder Reveals Shocking Valuation Concerns - StockTitan
Akoya climbs after merger deal with Quanterix - MSN
Piper Sandler Downgrades Akoya Biosciences to Neutral From Overweight, Adjusts Price Target to $2.40 From $3 - Marketscreener.com
Piper Sandler cuts Akoya Biosciences stock rating to Neutral - Investing.com
Piper Sandler cuts Akoya Biosciences stock rating to Neutral By Investing.com - Investing.com Canada
Quanterix Announces Acquisition of Akoya Biosciences - TipRanks
Quanterix Highlights Benefits Of Akoya Biosciences Acquisition -March 03, 2025 at 06:13 am EST - Marketscreener.com
Can Quanterix's Akoya Acquisition Transform Biomarker Detection and Deliver $1B Revenue? - StockTitan
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition - Bluefield Daily Telegraph
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 60.1% in February - Defense World
Akoya Biosciences (AKYA) to Release Earnings on Monday - MarketBeat
Akoya Biosciences’ Merger with Quanterix Moves Forward - Investing.com India
Quanterix advances towards Akoya Biosciences acquisition By Investing.com - Investing.com Australia
Akoya Biosciences' Merger with Quanterix Moves Forward By Investing.com - Investing.com South Africa
Quanterix advances towards Akoya Biosciences acquisition - Investing.com
Akoya Biosciences’ Merger with Quanterix Moves Forward By Investing.com - Investing.com UK
Akoya Biosciences stock hits 52-week low at $1.88 amid market challenges - Investing.com Australia
Finanzdaten der Akoya Biosciences Inc-Aktie (AKYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):